SCHEMBL146226

SCHEMBL146226

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4ccccc4)cc32)c(C)c1C(=O)NCCN(C(C)C)C(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRK5 P34947 4/20 0.59
KDR P35968 12/20 0.58
PRKAA1 Q13131 12/20 0.58
PRKAA2 P54646 11/20 0.58
PDGFRB P09619 6/20 0.58
FGFR1 P11362 5/20 0.58
EGFR P00533 3/20 0.57
FLT3 P36888 3/20 0.57
PLK4 O00444 2/20 0.57
DCLK1 O15075 2/20 0.57
PDPK1 O15530 2/20 0.57
DAPK3 O43293 2/20 0.57
ROCK2 O75116 2/20 0.57
RPS6KA5 O75582 2/20 0.57
RPS6KA4 O75676 2/20 0.57
MAP4K4 O95819 2/20 0.57
CHEK2 O96017 2/20 0.57
NTRK1 P04629 2/20 0.57
INSR P06213 2/20 0.57
LCK P06239 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL141064 0.92 KDR (0.61) GRK5KDRPRKAA1PRKAA2PDGFRB
SCHEMBL142711 0.91 KDR (0.71) GRK5KDRPRKAA1PRKAA2PDGFRB
SCHEMBL147851 0.90 KDR (0.59) GRK5KDRPRKAA1PRKAA2PDGFRB
SCHEMBL140610 0.86 KDR (0.70) GRK5KDRPRKAA1PRKAA2PDGFRB
SCHEMBL143571 0.85 ALK (0.63) KDRPRKAA1PRKAA2PDGFRBFGFR1
SCHEMBL142933 0.85 KDR (0.56) GRK5KDRPRKAA1PRKAA2PDGFRB
SCHEMBL144746 0.85 PRKAA1 (0.69) GRK5KDRPRKAA1PRKAA2PDGFRB
SCHEMBL142827 0.85 PRKAA1 (0.69) GRK5KDRPRKAA1PRKAA2PDGFRB
SCHEMBL145122 0.85 PRKAA1 (0.67) GRK5KDRPRKAA1PRKAA2PDGFRB
SCHEMBL7124494 0.84 KDR (0.65) GRK5KDRPRKAA1PRKAA2PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 GRK5 1887/4885KDR 1077/4885PRKAA1 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.